IBDEI17B ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19518,2)
 ;;=^5019488
 ;;^UTILITY(U,$J,358.3,19519,0)
 ;;=I69.320^^67^877^2
 ;;^UTILITY(U,$J,358.3,19519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19519,1,3,0)
 ;;=3^Aphasia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19519,1,4,0)
 ;;=4^I69.320
 ;;^UTILITY(U,$J,358.3,19519,2)
 ;;=^5007491
 ;;^UTILITY(U,$J,358.3,19520,0)
 ;;=I69.120^^67^877^3
 ;;^UTILITY(U,$J,358.3,19520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19520,1,3,0)
 ;;=3^Aphasia following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,19520,1,4,0)
 ;;=4^I69.120
 ;;^UTILITY(U,$J,358.3,19520,2)
 ;;=^5007427
 ;;^UTILITY(U,$J,358.3,19521,0)
 ;;=I69.020^^67^877^4
 ;;^UTILITY(U,$J,358.3,19521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19521,1,3,0)
 ;;=3^Aphasia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19521,1,4,0)
 ;;=4^I69.020
 ;;^UTILITY(U,$J,358.3,19521,2)
 ;;=^5007395
 ;;^UTILITY(U,$J,358.3,19522,0)
 ;;=I69.820^^67^877^5
 ;;^UTILITY(U,$J,358.3,19522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19522,1,3,0)
 ;;=3^Aphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19522,1,4,0)
 ;;=4^I69.820
 ;;^UTILITY(U,$J,358.3,19522,2)
 ;;=^5007522
 ;;^UTILITY(U,$J,358.3,19523,0)
 ;;=I69.220^^67^877^6
 ;;^UTILITY(U,$J,358.3,19523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19523,1,3,0)
 ;;=3^Aphasia following other nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,19523,1,4,0)
 ;;=4^I69.220
 ;;^UTILITY(U,$J,358.3,19523,2)
 ;;=^5007459
 ;;^UTILITY(U,$J,358.3,19524,0)
 ;;=I69.290^^67^877^11
 ;;^UTILITY(U,$J,358.3,19524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19524,1,3,0)
 ;;=3^Apraxia following other nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,19524,1,4,0)
 ;;=4^I69.290
 ;;^UTILITY(U,$J,358.3,19524,2)
 ;;=^5007484
 ;;^UTILITY(U,$J,358.3,19525,0)
 ;;=I69.390^^67^877^7
 ;;^UTILITY(U,$J,358.3,19525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19525,1,3,0)
 ;;=3^Apraxia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19525,1,4,0)
 ;;=4^I69.390
 ;;^UTILITY(U,$J,358.3,19525,2)
 ;;=^5007515
 ;;^UTILITY(U,$J,358.3,19526,0)
 ;;=I69.190^^67^877^8
 ;;^UTILITY(U,$J,358.3,19526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19526,1,3,0)
 ;;=3^Apraxia following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,19526,1,4,0)
 ;;=4^I69.190
 ;;^UTILITY(U,$J,358.3,19526,2)
 ;;=^5007452
 ;;^UTILITY(U,$J,358.3,19527,0)
 ;;=I69.090^^67^877^9
 ;;^UTILITY(U,$J,358.3,19527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19527,1,3,0)
 ;;=3^Apraxia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19527,1,4,0)
 ;;=4^I69.090
 ;;^UTILITY(U,$J,358.3,19527,2)
 ;;=^5007420
 ;;^UTILITY(U,$J,358.3,19528,0)
 ;;=I69.890^^67^877^10
 ;;^UTILITY(U,$J,358.3,19528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19528,1,3,0)
 ;;=3^Apraxia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19528,1,4,0)
 ;;=4^I69.890
 ;;^UTILITY(U,$J,358.3,19528,2)
 ;;=^5007546
 ;;^UTILITY(U,$J,358.3,19529,0)
 ;;=I69.393^^67^877^12
 ;;^UTILITY(U,$J,358.3,19529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19529,1,3,0)
 ;;=3^Ataxia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19529,1,4,0)
 ;;=4^I69.393
 ;;^UTILITY(U,$J,358.3,19529,2)
 ;;=^5007518
 ;;^UTILITY(U,$J,358.3,19530,0)
 ;;=I69.193^^67^877^13
 ;;^UTILITY(U,$J,358.3,19530,1,0)
 ;;=^358.31IA^4^2
